vimarsana.com

Latest Breaking News On - Appointing brenda marczi - Page 1 : vimarsana.com

Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation fr

With a Focus on Potential Pivotal Studies in 2025, Treadwell has Strengthened its Leadership Team by Appointing Brenda Marczi, PharmD, MBA as SVP and Head of Regulatory AffairsTORONTO & SAN FRANCISCO (BUSINESS WIRE) Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advanc.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.